Treatment of hypovitaminosis D in infants and toddlers

Divisions of Adolescent Medicine and Endocrinology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. .
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 08/2008; 93(7):2716-21. DOI: 10.1210/jc.2007-2790
Source: PubMed

ABSTRACT Hypovitaminosis D appears to be on the rise in young children, with implications for skeletal and overall health.
The objective of the study was to compare the safety and efficacy of vitamin D2 daily, vitamin D2 weekly, and vitamin D3 daily, combined with supplemental calcium, in raising serum 25-hydroxyvitamin D [25(OH)D] and lowering PTH concentrations.
This was a 6-wk randomized controlled trial.
The study was conducted at an urban pediatric clinic in Boston.
Forty otherwise healthy infants and toddlers with hypovitaminosis D [25(OH)D < 20 ng/ml] participated in the study.
Participants were assigned to one of three regimens: 2,000 IU oral vitamin D2 daily, 50,000 IU vitamin D2 weekly, or 2,000 IU vitamin D3 daily. Each was also prescribed elemental calcium (50 mg/kg.d). Infants received treatment for 6 wk.
Before and after treatment, serum measurements of 25(OH)D, PTH, calcium, and alkaline phosphatase were taken.
All treatments approximately tripled the 25(OH)D concentration. Preplanned comparisons were nonsignificant: daily vitamin D2 vs. weekly vitamin D2 (12% difference in effect, P = 0.66) and daily D2 vs. daily D3 (7%, P = 0.82). The mean serum calcium change was small and similar in the three groups. There was no significant difference in PTH suppression.
Short-term vitamin D2 2,000 IU daily, vitamin D2 50,000 IU weekly, or vitamin D3 2,000 IU daily yield equivalent outcomes in the treatment of hypovitaminosis D among young children. Therefore, pediatric providers can individualize the treatment regimen for a given patient to ensure compliance, given that no difference in efficacy or safety was noted among these three common treatment regimens.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D deficiency may represent a modifiable risk factor to improve outcome in severe illness. The efficacy of high-dose regimens in rapid normalization of vitamin D levels is uncertain. We conducted a systematic review of pediatric clinical trials administering high-dose vitamin D to evaluate 25-hydroxyvitamin D (25[OH]D) response and characteristics associated with final 25(OH)D levels by using Medline, Embase, and the Cochrane Central Register of Controlled Trials, including reference lists of systematic reviews and eligible publications. Uncontrolled and controlled trials reporting 25(OH)D levels after high-dose (≥1000 IU) ergocalciferol or cholecalciferol were selected. Two reviewers independently extracted and verified predefined data fields. We identified 88 eligible full-text articles. Two of 6 studies that administered daily doses approximating the Institute of Medicine's Tolerable Upper Intake Level (1000-4000 IU) to vitamin D-deficient populations achieved group 25(OH)D levels >75 nmol/L within 1 month. Nine of 10 studies evaluating loading therapy (>50 000 IU) achieved group 25(OH)D levels >75 nmol/L. In meta-regression, baseline 25(OH)D, regimen type, dose, age, and time factors were associated with final 25(OH)D levels. Adverse event analysis identified increased hypercalcemia risk with doses >400 000 IU, but no increased hypercalcemia or hypercalciuria with loading doses <400 000 IU (or 10 000 IU/kg). Few studies in adolescents evaluated loading dose regimens >300 000 IU. Rapid normalization of vitamin D levels is best achieved by using loading therapy that considers disease status, baseline 25(OH)D, and age (or weight). Loading doses >300 000 IU should be avoided until trials are conducted to better evaluate risk and benefit. Copyright © 2015 by the American Academy of Pediatrics.
    Pediatrics 12/2014; 135(1). DOI:10.1542/peds.2014-1703 · 5.30 Impact Factor
  • Journal of Medical Biochemistry 01/2013; 32(1):1-58. DOI:10.2478/v10011-012-0025-y · 1.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine whether vitamin D supplementation of indigenous school children living at high altitude who are vitamin D insufficient improves lipid profile. Methods: A prospective two-year study evaluated 60 children (29 males) from Hogar School who received 100,000 units of vitamin D and 36 children (16 males) from Sosa School who received 50,000 units. Anthropometric measures, Triglycerides (TG), HDL-C, TG/HDL-C, and vitamin D levels were measured in November 2011 and in November 2013. Results: Children aged 8.8±2 years with mean z-BMI (-0.43) were evaluated. After vitamin D supplementation, mean vitamin D levels increased from 14.7 to 32.1ng/mL (p Conclusions: Indigenous children who received 100,000 U of vitamin D significantly improved vitamin D and lipid levels compared to children who received 50,000 U, suggesting that optimal vitamin D levels are associated with a healthier lipid profile.
    Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents) 01/2014; 12(1).

Full-text (2 Sources)

Available from
May 21, 2014